TEST ID HYPOG Hypoglycemic Agent Screen, Serum
Reporting Name
Hypoglycemic Agent Screen, SSpecimen Type
Serum RedSpecimen Required
Patient Preparation: Specimen must be collected during an episode of hypoglycemia.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume:1.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum Red | Frozen (preferred) | 28 days | |
Refrigerated | 28 days | ||
Ambient | 7 days |
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reject Due To
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Reference Values
Negative
Screening cutoff concentrations
Chlorpropamide: 100 ng/mL
Glimepiride: 20 ng/mL
Glipizide: 5 ng/mL
Glyburide: 5 ng/mL
Nateglinide: 5 ng/mL
Pioglitazone: 20 ng/mL
Repaglinide: 5 ng/mL
Rosiglitazone: 20 ng/mL
Tolazamide: 50 ng/mL
Tolbutamide: 20 ng/mL
Note: If a drug is detected at a concentration greater than the cutoff, the report will indicate that specific drug is positive. The test cutoff listed for each drug is lower than the concentration that will cause increased insulin and decreased glucose.
Day(s) Performed
Monday, Wednesday, Friday
Report Available
2 to 6 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
80377
G0480-(if appropriate)
Forms
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
Useful For
Evaluation of suspected insulinoma characterized by hypoglycemia and increased serum insulin concentration
Detecting drugs that stimulate insulin secretion
Drugs detected by this procedure are:
-The first-generation sulfonylureas: chlorpropamide (Diabinese), tolazamide, and tolbutamide (Orinase)
-The second-generation sulfonylureas: glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (Glibenclamide)
-The meglitinides: repaglinide (Prandin) and nateglinide (Starlix)
-The thiazolidinediones: pioglitazone (Actos) and rosiglitazone (Avandia)
This test is not intended for therapeutic drug monitoring but could be used to monitor compliance.
Highlights
If hypoglycemia is the result of an insulin-stimulating drug, this test will detect the drug at physiologically significant concentrations during an episode of hypoglycemia.